25 results match your criteria: "Paterson Institute of Cancer Research[Affiliation]"
J Pathol
September 2013
Cancer Biology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Levels of caveolin-1 (Cav-1) in tumour epithelial cells increase during prostate cancer progression. Conversely, Cav-1 expression in the stroma can decline in advanced and metastatic prostate cancer. In a large cohort of 724 prostate cancers, we observed significantly decreased levels of stromal Cav-1 in concordance with increased Gleason score (p = 0.
View Article and Find Full Text PDFHum Gene Ther
June 2010
Cellular Therapy Group, School of Cancer and Enabling Sciences, The Paterson Institute of Cancer Research, The University of Manchester, Wilmslow Road, Manchester, UK.
Adoptive cellular therapy provides the promise of a potentially powerful general treatment for cancer. Although this is a complex and challenging field, there have been major advances in basic and translational research resulting in clinical trial activity that is now beginning to confirm this promise. However, these trials are also identifying new challenges and this review focuses on these clinical issues.
View Article and Find Full Text PDFBr J Cancer
August 2008
Clinical and Experimental Pharmacology, Paterson Institute of Cancer Research, Manchester, UK.
Hypoxia inducible factor 1 (HIF-1) represses the transcription of pro-apoptotic bid in colorectal cancer cells in vitro. To assess the clinical relevance of this observation, HIF-1alpha and Bid were assessed in serial sections of 39 human colorectal adenocarcinomas by immunohistochemistry. In high HIF-1alpha nuclear-positive cell subpopulations, there was a significant reduction in Bid expression (ANOVA, P=0.
View Article and Find Full Text PDFBiomark Insights
January 2008
Clinical and Experimental Pharmacology, Paterson Institute of Cancer Research, Wilmslow Road, Manchester M20 4BX.
Free circulating DNA, which is thought to be derived from the primary tumour, can be detected in the blood of patients with cancer. Detection of genetic and epigenetic alteration in this tumour DNA offers a potential source of development of prognostic and predictive biomarkers for cancer. One such change is DNA methylation of the promotor region of tumour suppressor genes.
View Article and Find Full Text PDFLancet
January 2007
Cancer Research UK Children's Cancer Group, Paterson Institute of Cancer Research, University of Manchester, Manchester M20 4BX, UK.
Cancer Immunol Immunother
February 2007
CRUK Immunology Group, Paterson Institute of Cancer Research, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK.
We have investigated the tumour therapeutic efficacy of homologous and heterologous prime-boost vaccine strategies against the 5T4 oncofoetal antigen, using both replication defective adenovirus expressing human 5T4 (Ad5T4), and retrovirally transduced DC lines (DCh5T4) in a subcutaneous B16 melanoma model (B16h5T4). In naïve mice we show that all vaccine combinations tested can provide significant tumour growth delay. While DCh5T4/Adh5T4 sequence is the best prophylactic regimen (P > 0.
View Article and Find Full Text PDFAngiogenesis
March 2005
Cancer Research UK, Department of Medical Oncology, Paterson Institute of Cancer Research/Christie Hospital, Manchester, UK.
The development of agents that target tumour vasculature is ultimately dependent on the availability of appropriate preclinical screening assays. Several quantitative angiogenesis assays exist, each with its own unique characteristics and disadvantages. In this review we discuss some of the commonly used assays, their methodological pitfalls and current use.
View Article and Find Full Text PDFJ Immunother
December 2004
Cancer Research UK Department of Medical Oncology, Paterson Institute of Cancer Research, Christie Hospital NHS Trust, Manchester, UK.
There is extensive interest in idiotypic vaccination as a treatment of lymphoma. An alternative approach is the adoptive transfer of in vitro generated T cells. This strategy has been used to treat posttransplantation EBV-related diseases.
View Article and Find Full Text PDFExpert Rev Vaccines
October 2002
Department of Medical Oncology, Paterson Institute of Cancer Research, Christie Hospital NHS Trust, Manchester, UK.
Observations that cells of the immune system are able to kill tumor cells both in vitro and in animal models have provided a compelling rationale for pursuit of a strategy whereby immune cells are administered as a therapeutic vaccine to patients with cancer. The successful outcome of this approach depends upon the ability to deliver this therapy in a manner in which a potent immune response is elicited. By harnessing the capacity of dendritic cells that are pivotal in priming the immune response and using gene therapy approaches to optimise the immune response, this may ultimately prove efficacious in the management of human cancer.
View Article and Find Full Text PDFMethods Mol Biol
June 2003
CR-UK Department of Cancer Genetics, Paterson Institute of Cancer Research, Manchester.
Germline TP53 mutations are responsible for the large majority of classic LFS families, and a smaller proportion of LFL families. In some of the families shown to have no germline TP53 mutation, germline hChk2 mutations have been described. In some cases the functional consequences of the latter have been demonstrated, although there are still relatively few reports of such mutations.
View Article and Find Full Text PDFJ Immunol
April 2002
Department of Medical Oncology and Immunology, Cancer Research Campaign, Paterson Institute of Cancer Research, Christie Hospital National Health Service Trust, Manchester, United Kingdom.
The Ig Id of a B cell lymphoma is a tumor-specific Ag, although as a self-Ag it is likely to be a weak immunogen. Provision of a foreign gene may enhance the immunogenicity of the idiotype. Viral vectors allow highly efficient transfer of genetic material and are themselves innately immunogenic.
View Article and Find Full Text PDFBMJ
December 2001
Cancer Research Campaign Department of Medical Oncology, Paterson Institute of Cancer Research, Christie Hospital NHS Trust, Manchester M20 4BX.
Gene Ther
October 2000
Cancer Research Campaign Laboratories, Paterson Institute of Cancer Research, Christie Hospital, Manchester, UK.
The identification of dendritic cells (DC) as the major antigen-presenting cell type of the immune system, combined with the development of procedures for their ex vivo culture, has opened possibilities for tumour immunotherapy based on the transfer of recombinant tumour antigens to DC. It is anticipated that the most effective type of response would be the stimulation of specific, MHC class I restricted cytotoxic T lymphocytes capable of recognising and destroying tumour cells. In order to make this approach possible, methods must be developed for the transfer of recombinant antigen to the DC in such a way that they will initiate an MHC class I restricted response.
View Article and Find Full Text PDFJ Biol Chem
September 1999
Cancer Research Campaign, Paterson Institute of Cancer Research, Christie Hospital, Wilmslow Road, Manchester M20 4BX, United Kingdom.
The oligodendrocyte-type-2 astrocyte progenitor cells (precursors of oligodendrocytes and type-2 astrocytes) are an excellent system in which to study differentiation as they can be manipulated in vitro. Maintenance of oligodendrocyte-type-2 astrocyte progenitor cells requires basic fibroblast growth factor, a growth factor whose action normally depends on a heparan sulfate coreceptor. Biochemical analysis revealed a most surprising result: that the oligodendrocyte-type-2 astrocyte progenitors did not synthesize heparan sulfate, the near ubiquitous N-sulfated cell surface polysaccharide, but the chemically related heparin in a form that was almost completely N- and O-sulfated.
View Article and Find Full Text PDFBone Marrow Transplant
July 1998
Cancer Research Campaign Department of Experimental Haematology, Paterson Institute of Cancer Research, Christie Hospital, Manchester, UK.
The addition of stem cell factor (SCF) to G-CSF and chemotherapy results in a dose-dependent, significantly increased mobilisation of peripheral blood progenitor cells compared with the use of chemotherapy and G-CSF alone. The enhanced mobilisation may benefit patients in several ways. Firstly, in clinical settings where currently multiple aphereses are having to be performed to obtain a specified target number of cells, the addition of SCF may lead to a reduction in this number.
View Article and Find Full Text PDFBlood
January 1997
CRC Department of Experimental Haematology, Paterson Institute of Cancer Research, Christie Hospital, Manchester, UK.
We have identified a gene that has a high level of mRNA expression in undifferentiated, multipotential hematopoietic cells (FDCP-Mix) and that downregulates both transcript and protein, as these cells are induced to differentiate into mature myeloid cells. Sequence analysis of this gene has identified it as a serine protease inhibitor EB22/3 (serpin 2A). Constitutive expression of serpin 2A in FDCP-Mix cells was associated with an increase in the clonogenic potential of the cells and with a delay in the appearance of fully mature cells in cultures undergoing granulocyte macrophage differentiation when compared with control cells.
View Article and Find Full Text PDFNucleic Acids Res
December 1996
Department of Experimental Haematology, Paterson Institute of Cancer Research, Christie Hospital, Manchester, UK.
We describe a method of global PCR amplification of cDNA such that the strand sense is maintained. The products of this process are random primed fragments ranging in size from 100 to 500 bp which facilitates uniform PCR amplification of total cDNA. Directional incorporation of a T7 RNA polymerase initiator/promoter sequence allows efficient synthesis of total sense RNA from this material and the use of a biotinylated primer permits the separation of single-stranded cDNA.
View Article and Find Full Text PDFHum Genet
June 1995
CRC Department of Cancer Genetics, Paterson Institute of Cancer Research, Christie (CRC) Research Trust, Manchester, UK.
A patient with Beckwith-Wiedemann syndrome (BWS) presented with Wilms' tumour. Examination of the nephrectomy specimen showed, in addition to the tumour, the presence of nephrogenic rests. Nephrogenic rests are thought to be precursor lesions from which a Wilms' tumour may develop.
View Article and Find Full Text PDFBr J Cancer
May 1994
Department of Immunology, Paterson Institute of Cancer Research, Christie Hospital, NHS Trust, Manchester, UK.
The 5T4 oncofetal antigen is a 72 kDa glycoprotein defined by a monoclonal antibody raised against human placental trophoblast and is expressed in many different carcinomas but detected only at low levels in some normal epithelia. Immunohistochemical analysis of the patterns of expression in colorectal carcinomas has indicated a significant association between the presence of the antigen in tumour cells and metastatic spread. The 5T4 antigen phenotype of 72 colorectal cancers has been compared with the clinical outcome of the patients in order to assess its relationship with prognosis.
View Article and Find Full Text PDFEpithelial Cell Biol
November 1995
CRC Department of Epithelial Biology, Paterson Institute of Cancer Research, Christie Hospital (NHS) Trust, Manchester, UK.
Migration velocity estimates have been determined at each position along the crypt length for both the small and large intestine of the mouse at 6 different times of the day. Measurements also have been made of crypt circumference and length. Dramatic, and significant (P < 0.
View Article and Find Full Text PDFCancer Res
May 1993
CRC Department of Epithelial Biology, Paterson Institute of Cancer Research, Christie Hospital National Health Service Trust, Manchester, United Kingdom.
Previous studies have shown that DNA cleavage by mammalian topoisomerase II is ATP dependent and can be inhibited by metabolic inhibitors. Furthermore, it has been shown that metabolic inhibitors also have a cytoprotective effect in vitro against topoisomerase II-targeting antitumor drugs. However, the nature of the ATP-dependent process is not known.
View Article and Find Full Text PDFBiochem Pharmacol
April 1992
CRC Department of Epithelial Biology, Paterson Institute of Cancer Research, Christie Hospital NHS Trust, Manchester, U.K.
The processes involved in cell killing by Adriamycin (ADR) and other agents that interact with topoisomerase II are unclear. To investigate the mode of ADR cytotoxicity in vivo, we have investigated the effects of the protein synthesis inhibitor, cycloheximide (CH), on cell killing by ADR in the murine intestinal tract. We have used morphological criteria to assay the cell death.
View Article and Find Full Text PDFNucleic Acids Res
March 1992
CRC Department of Cancer Genetics, Paterson Institute of Cancer Research, Manchester, UK.
Hum Genet
April 1990
Department of Biochemical Genetics, Paterson Institute of Cancer Research, Christie Hospital and Holt Radium Institute, Manchester, UK.
Human X rodent hybrids were stained by indirect immunofluorescence with 5T4, a murine monoclonal antibody that recognises a 72 kdalton glycoprotein expressed by human trophoblasts and a very restricted range of adult tissues; they were analysed by flow cytometry. Concordance analysis supported by segregation data allowed assignment of the gene controlling glycoprotein expression (M6P1) to chromosome 6. Similar analysis with translocation hybrids gave a regional assignment to 6q14-q15.
View Article and Find Full Text PDF